Treating eye disorders intestinal trefoil proteins
AssigneeThe General Hospital Corporation
InventorDaniel K. Podolsky
Life of this patent
Estimating the term…
Abstract
Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistant to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases, eye disorders and other insults.
Claims21
A method for the treatment of a disruption of the corneal epithelium in a pateint, said method comprising administering to the eye of said patient a trefoil protein selected from the group consisting of intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2, and biologically active fragments thereof.
A method for the treatment of a disruption of the corneal epithelium in a patient, said method comprising administering to the eye of said patient a trefoil protein comprising a region having at least 90% sequence identity to residues 33-70 of the polypeptide set forth in SEQ ID NO:
- 2, or at least 90% sequence identity to residues 25-62 of the polypeptide set forth in SEQ ID NO:
- 4, wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.
A method for the treatment of a disruption of the corneal epithelium in a patient, said method comprising administering to the eye of said patient a trefoil protein comprising a region having at least 90% sequence identity, over more than 35 contiguous amino acid residues, to the polypeptide set forth in SEQ ID NO:
- 2 or 4, wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.
Dependencies are inferred from the claim text.